XILIO THERAPEUTICS, INC. (XLO)
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
HONEYWELL TECHNOLOGIES TO RELEASE SECOND QUARTER FINANCIAL RESULTS, DISCUSS 2026 OUTLOOK AND HOLD ITS INVESTOR CONFERENCE CALL ON THURSDAY, JULY 23
Streamex Corp. Brings Yield-Bearing Gold (GLDY) to Traditional Brokerage Accounts Through Collaboration with Siebert Financial and tZERO
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves Disease
FuelCell Energy Secures $49 Million in EXIM Financing to Advance U.S. Clean Energy Exports
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Valmont Releases 2026 Sustainability Report
FreightCar America, Inc. Joins Russell 2000® and Russell 3000® Indexes
Twin Disc, Inc. Joins Russell 2000® and Russell 3000® Indexes